Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Keymed Biosciences Pretax Margin % Related Terms
Keymed Biosciences Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Keymed Biosciences's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:64Z vs VRTX, REGN, RVMD: Pretax Margin % Comparison
For the Biotechnology subindustry, Keymed Biosciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Keymed Biosciences Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Keymed Biosciences's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Keymed Biosciences's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keymed Biosciences (FRA:64Z) has a Pretax Margin % of -204.56% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Keymed Biosciences and its competitors. According to the industry distribution chart, Keymed Biosciences ranks #458 out of 945 companies in the Biotechnology industry, placing it in the top 48.5%.
Is Keymed Biosciences' Pretax Margin % too high?
Keymed Biosciences' current Pretax Margin % is -204.56%. Based on the distribution chart, Keymed Biosciences ranks #458 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Keymed Biosciences has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Keymed Biosciences' Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Keymed Biosciences ranks #458 out of 945 companies for Pretax Margin %. This puts Keymed Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Keymed Biosciences and its competitors. Keymed Biosciences's current Pretax Margin % is -204.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keymed Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Keymed Biosciences (FRA:64Z) is currently considered Possible Value Trap. The stock's GF Value™ is €18.50, compared to a current price of €8.45 — trading 54.3% below its estimated fair value. The current Pretax Margin % is -204.56%. Keymed Biosciences' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Keymed Biosciences (FRA:64Z), the current Pretax Margin % is -204.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Keymed Biosciences (FRA:64Z) Overvalued in 2026?
Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued.
The current stock price of €8.45 is trading 54.3% below its estimated GF Value™ of €18.50.
GuruFocus considers Keymed Biosciences to be Possible Value Trap.
Key valuation signals for FRA:64Z:
Pretax Margin %: -204.56%
GF Value™: €18.50 vs. price of €8.45 (54.3% below fair value)
No single metric tells the full story. See the FRA:64Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
44GF Score
Get the complete analysis for FRA:64Z
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:64Z has been successfully added to your 
